Abstract 5771
Background
Hyponatremia, usually defined as the sodium serum level < 135 mEq/l (mmol/l), is a common electrolyte disorder in the clinical practice.1 Despite its often benign course, it can rapidly evolve into a life threatening condition mainly due to neurological symptoms. Moreover, in cancer patients, hyponatremia is significantly associated with reduced overall survival.2 In cancer patients hyponatremia can occur due to malignancy as well as chemotherapy.3 Many chemotherapy drugs have been reported to induce hyponatremia.4 This study aims to determine which chemotherapeutic drugs used in hematological patients are mostly associated with hyponatremia.
Methods
This study analyzed retrospectively the data from 189 patients with diagnosed haematological malignancies that developed hyponatremia while undergoing chemotherapy. The period of observation was determined to start at the first day of a chemotherapy cycle until the 3rd day after the end of a cycle. For the purpose of this study, hyponatremia was defined as serum sodium level < 135 mEq/l (mmol/l).
Results
In our cohort of 189 patients with hyponatremia the most predominant hematological malignancy was Multiple Myeloma, which was present in 56 (29.6%) of the included patients and was followed by diffuse large B-cell Lymphoma with 34 (13.2%) patients. The median age of the studied cohort was 68 years (range 33-84 years).The mean value of serum sodium was 130.4 ± 0.27 mEq/l. 42 (22.4 %) patients had hyponatremia in the 4th cycle of the chemotherapy, with 101 (53.4%) patients developing hyponatremia in the first 4 cycles of the chemotherapy. From all patients with hyponatremia (n = 189), 43 (22.7%) received Cyclophosphamide, 38 (20.1%) Vincristine, 85 (44.9%) Cyclophosphamide and Vincristine as part of a combination, 20 (10.5%) Methothrexate, 18 (9.5%) Cisplatin and 8 (4.2%) Daratumumab.
Conclusions
Patient with hematological malignancies are at increased risk of hyponatremia possibly induced by chemotherapy. The combination regimens seem to increase the risk of developing hyponatremia substantially. In which way the occurrence of hyponatremia depends on cofactors such as infusion schemas or tumor lysis has to be evaluated in prospective studies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract